iRegene Therapeutics
PrivateLast Round
Series C
Extension
Jul 2, 2026
Total Funding Raised
$170.7M
Company Overview
iRegene Therapeutics is a biotechnology company that develops chemically induced allogeneic cell therapies for the treatment of degenerative diseases such as Parkinson's disease.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Medical AI, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Infrastructure
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
iRegene Therapeutics Comparables
Compare iRegene Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| XellSmart | 88% | |
| Kenai Therapeutics | 85% | |
| Aspen Neuroscience | 81% | |
iRegene Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C Extension | Jul 2, 2026 | ||||
| Series C | Jun 1, 2026 | ||||
| Series B | Sep 4, 2025 | ||||
| Series B Extension | Apr 11, 2025 | ||||
| Series B | Oct 13, 2024 | ||||
Series A Extension | Jan 24, 2022 |
iRegene Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Ceyuan Ventures | Series B |
| Shanghai Guosheng Capital Management Co., Ltd. | Series B |
| China Capital Management Co., Ltd. | Series C Extension |
| Shenzhen New Industry Venture Capital | VC Round |
| Northern Light Venture Capital | Series B |
| Hony Capital | Series C Extension |
| Shenzhen Dachen Caizhi Venture Capital Management | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 23, 2026
Monthly visitors grew 386% MoM to 525.
- Apr 11, 2025
$14M raised in Series B Extension round.
iRegene Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about iRegene Therapeutics's valuation, stock price, and market status.